The Undetected and unexpected allergens in cosmetics

MUDr. Alena Machovcová MBA

Dermatol. praxi. 2007;1(1)

Cosmetic contact hypersensitivity is commonly seen in patients after long-lasting and repeated application of cosmetics. It may be caused by active ingredients but also by other ingredients with low sensitisation capacity. The cosmetic business is a dynamic, lucrative and fast-moving industry in which new chemicals are developed. New allergens are always being produced. The aim of article was to give notice about some of the new cosmetic allergens.

Atopy patch tests with airborn allergens

MUDr. Miroslav Nečas

Dermatol. praxi. 2007;1(1)

Recently atopy patch tests as a new diagnostic method is introduced in the clinical practice. This article reviews actual results and experience regarding atopy patch tests with airborn allergens (aeroallergens). There are still certain problems with the stardandization (especially the concentration) of the allergens. As soon as these problems are solved, this metod could become a component of the routine diagnostic procedure in patiens with atopic dermatitis.

INDICATIONS FOR IMMUNOLOGICAL AND ALLERGOLOGICAL EXAMINATION IN CASES OF SKIN DISEASE

doc. MUDr. Marie Viktorinová CSc

Dermatol. praxi. 2007;1(1)

The article describes a survey of immunological and allergological examinations, which assist in etiopathogenetic diagnosis in dermatology. These examinations should always be carried out specifically based on detailed case history, clinical picture of skin symptoms and basic laboratory tests: sedimentation of blood, complete blood count and selected biochemical tests. Physical skin tests are also introduced within the framework of a differential diagnosis of chronic urticarias.

Biologicals in the treatment of severe forms of psoriasis

MUDr. Martin Tichý Ph.D, doc. MUDr. Dagmar Ditrichová CSc

Dermatol. praxi. 2007;1(1)

Psoriasis is a chronic inflammatory disorder with strong negative impact on quality of life. The goal of the therapeutic methods is reduction of disease activity and clinical symptoms together with minimising of adverse events. The need for therapies that are both effective and safe for long-term continuous use, together with advances in our understanding of the immunopathogenesis of psoriasis, have led to the development of new biological therapies with more selective mechanisms of action and improved safety.

Barrier function of the skin in clinical practice

prof. MUDr. Jiří Záhejský DrSc

Dermatol. praxi. 2007;1(1)

Recent knowledge about the skin barrier and its function confirms its importance in the protection of the organism against adverse environmental factors. This protection lies in the regulation of penetration of chemical substances,in the protection against bacterial and fungal infections as well as against the adverse influences of ultraviolet radiation. The disturbance of the barrier function may lead to the development of various disorders of the skin. This article gives the information about factors leading to the barrier function disturbance, about the results of this disturbance as well as about the possibilities of its prevention and barrier...

Allergy - systemic disease with topical manifestatios

MUDr. Václava Gutová

Dermatol. praxi. 2007;1(1)

The allergy as a systemic immunopathologic response of organism is discussed in this rewiew from the point of view of contemporary knowledge of patogenetic mechanisms on cellular and molecular levels. These common mechanisms are asserted in pathogenesis of various organ manifestations in skin, repiratory tract tissue or the whole body.

Biologica treatment of psoriatic arthritis

MUDr. Liliana Šedová, MUDr. Jiří Štolfa

Dermatol. praxi. 2007;1(1)

Psoriatic arthritis is a chronic inflammatory disease characterized by the manifestations of arthritis and psoriasis. Treatment of the disease is expected to decrease or to suppress the activity of arthritis and enthesitis or to retard the radiological progression and to clear the skin and nail signs of the disease or not to worsen them at least. Standard treatment of psoriatic arthritis includes nonsteroidal anti-inflammatory drugs, disease modifying drugs, glucocorticosteroids and TNFα inhibitors. Anti TNFα antagonists, e.g. infliximab, adalimumab and etanercept are agents with different structure, which influence the inflammatory cascade...

Pemphigoid gestationis léčený celkově kortikoidy

MUDr. Iva Karlová, MUDr. Martin Tichý Ph.D

Dermatol. praxi. 2007;1(1)

Pyoderma gangrenosum

prof. MUDr. Karel Pizinger CSc

Dermatol. praxi. 2007;1(1)

Biologická léčba chronické ložiskové psoriázy se známkami psoriatické artritidy

MUDr. Yvetta Vantuchová, MUDr. Eva Svobodová

Dermatol. praxi. 2007;1(1)

Diferenciální diagnostika a léčba alergických projevů na rukou

MUDr. Zuzana Kulíková

Dermatol. praxi. 2007;1(1)

Onemocnění ekzémová a profesionální dermatózy, Brno 24. 11. 2006

MUDr. Andrea Vocilková

Dermatol. praxi. 2007;1(1):43